Tag: Novartis AG (NYSE:NVS)


Novartis AG (NYSE:NVS) Signs Agreement With Artios Pharma For DDR Targets For Enhancing Radioligand Drugs

Novartis AG (NYSE:NVS) has entered an agreement with UK-based Artios Pharma to access DNA damage response targets having the potential of enhancing its radioligand drugs. The agreement will center around the development of cancer treatments through next-generation DDR targets discovery and validation. Novartis enters agreement with Artios According to the […]